Evolving Guidelines for the Use of Touch During a Clinical Trial of Group Psilocybin-Assisted Therapy

This technical report (2024) describes the evolving guidelines for facilitator use of touch in a group retreat-based format of psilocybin-assisted therapy. The primary goal is to create a safe and supportive haptic experience during sessions, with a secondary goal of maintaining therapeutic boundaries and responding to participant experiences with empathy.

Abstract of Evolving Guidelines for the Use of Touch During a Clinical Trial of Group Psilocybin-Assisted Therapy

“For a new clinical trial testing a group retreat-based format of psilocybin-assisted therapy, our research team created an initial set of practice guidelines that aimed to describe facilitator use of touch in a way that is ethical, supportive, and minimizes harm. In our first three retreats, however, we had two unexpected experiences with touch that led us to iterate our initial guidelines into a new version of guidelines. In this Technical Report, we describe our evolving guidelines specifying acceptable practices for facilitator use of touch to ensure a safe, supportive, and therapeutic participant experience. Our primary goal with these guidelines is to create a haptic experience during the psilocybin session that reinforces the participants’ sense of safety and supports their own experience during the psilocybin session. Our secondary goal is to allow the facilitator team to notice and maintain therapeutic boundaries and to respond to participant experiences with empathy and openness in the context of those boundaries.”

Authors: Anthony Back, Susanna Myers, John Guy, Juliana Perez, Leslie Lazar Thorn & Bonnie McGregor

Summary of Evolving Guidelines for the Use of Touch During a Clinical Trial of Group Psilocybin-Assisted Therapy

Recent reports of practitioners using touch unethically caused harm to clients, mentees, patients, and study participants. Our research team created its own practice guidelines to ensure that practitioners use touch in a way that is ethical, supportive, and minimizes harm.

Touch is one of the first ways babies bond with their mothers, and humans can distinguish different emotions and meanings through touch with surprising accuracy.

Non-psychedelic therapy generally refrains from touching clients, but some psychedelic practitioners believe that touch used carefully can be supportive and even important.

To access this content, you must purchase one of the following memberships: Sprout Membership, Pro Membership, Pro Membership Unlimited, Business Membership or Business Membership Unlimited. The membership will give you access to exclusive data, including summaries of psychedelic research papers, extended company info, and our member-only visualisations. Save yourself multiple hours each week by accessing Blossom’s resource library.

Find this paper

Evolving Guidelines for the Use of Touch During a Clinical Trial of Group Psilocybin-Assisted Therapy

https://doi.org/10.1089/psymed.2023.0069

Paywall | Google Scholar | Backup | 🕊

Cite this paper (APA)

Back, A., Myers, S., Guy, J., Perez, J., Lazar Thorn, L., & McGregor, B. (2024). Evolving Guidelines for the Use of Touch During a Clinical Trial of Group Psilocybin-Assisted Therapy. Psychedelic Medicine.

Study details

Compounds studied
Psilocybin

Institutes

Institutes associated with this publication

University of Washington in Seattle
Research into the therapeutic potential of psychedelics is underway at Washington State University.

Linked Clinical Trial

Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer
This phase I/II trial (n=56) will study the safety and side effects of psilocybin in combination with therapy for treating cancer-related anxiety in patients with metastatic cancer. Psilocybin is being studied to treat anxiety or depression in patients with advanced cancer. Participants will receive psilocybin orally and participate in group and individual therapy sessions.